(0.02%) 5 071.63 points
(-0.11%) 38 461 points
(0.10%) 15 713 points
(0.04%) $82.84
(-0.54%) $1.644
(-0.41%) $2 328.90
(-0.61%) $27.20
(-1.11%) $912.60
(0.09%) $0.935
(0.76%) $10.99
(-0.05%) $0.803
(-0.92%) $92.33
@ $40.50
发出时间: 9 Apr 2024 @ 21:36
回报率: -3.41%
上一信号: Apr 9 - 00:23
上一信号:
回报率: 0.25 %
Live Chart Being Loaded With Signals
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally...
Stats | |
---|---|
今日成交量 | 597 776 |
平均成交量 | 1.04M |
市值 | 4.97B |
EPS | $0 ( 2024-02-20 ) |
下一个收益日期 | ( $0.690 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 18.63 |
ATR14 | $0.0220 (0.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-17 | Labarre Michael J. | Buy | 10 000 | Common Stock |
2024-04-17 | Labarre Michael J. | Sell | 10 000 | Common Stock |
2024-04-16 | Labarre Michael J. | Sell | 10 000 | Common Stock |
2024-04-16 | Labarre Michael J. | Sell | 10 000 | Option to Purchase Common Stock |
2024-04-17 | Labarre Michael J. | Sell | 10 000 | Option to Purchase Common Stock |
INSIDER POWER |
---|
15.86 |
Last 100 transactions |
Buy: 612 606 | Sell: 449 990 |
音量 相关性
Halozyme Therapeutics Inc 相关性 - 货币/商品
Halozyme Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $829.25M |
毛利润: | $636.89M (76.80 %) |
EPS: | $2.13 |
Q4 | 2023 |
营收: | $230.04M |
毛利润: | $177.74M (77.27 %) |
EPS: | $0.660 |
Q3 | 2023 |
营收: | $216.03M |
毛利润: | $161.21M (74.62 %) |
EPS: | $0.620 |
Q2 | 2023 |
营收: | $221.04M |
毛利润: | $170.97M (77.35 %) |
EPS: | $0.570 |
Financial Reports:
No articles found.
Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。